Orthox Limited, a clinical stage company developing medical implants to repair damaged knee articular cartilage and other orthopaedic injuries, has secured a further USD4.3 million (GBP3.2 million) investment to close its USD12.5 million (GBP9.2 million) Series A financing round.
The financing will support further clinical trials of its lead product, FibroFix, at Southmead Hospital Bristol, UK and in Budapest, Hungary.
The current financing was led by Parkwalk, a UK active investor in the university spin-out sector, joined by existing shareholders including Oxford Technology & Innovations EIS Fund (OTIF), advised by Oxford Investment Consultants LLP, and Perivoli Innovations. New investors participating include experienced life science fund managers, Additio Investment Group.
